Tela Bio Secures Up To $50 Million In Debt Financing From Midcap Financial
Amount Raised
$50 Million
Description
TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company has entered into a new credit facility with MidCap Financial (“MidCap”), providing TELA with access to up to $50 million in total credit. A portion of the proceeds from the new credit facility were used to fully repay TELA’s existing $30 million credit facility with OrbiMed Royalty Opportunities II, LP, with the remaining proceeds under the credit facility available for working capital needs and other corporate purposes.
FundzWatch™ Score
Buyer Intent Analysis
Get personalized insights on buying likelihood